

**Tchaikapharma High Quality Medicines Inc.**  
**Consolidated Statement of financial position**  
**as of 31 december 2021**

	Applica tion	2021	2020
		BGN'000	BGN'000
<b>Non-current assets</b>			
Property, plant and equipment	1	38 071	37 333
Intangible Assets and Goodwill	2	3 451	3 816
TradeReceivables	4	5 276	5 157
<b>Non-current assets</b>		<b>46 798</b>	<b>46 306</b>
Inventories	5	11 342	10 842
Trade and other receivables	5	59 220	60 084
Current tax assets	5	40	14
Treasury shares	4	-	1
Cash and cash equivalents	6	57	64
<b>Current Assets</b>		<b>70 659</b>	<b>71 005</b>
<b>Assets</b>		<b>117 457</b>	<b>117 311</b>
Issued capital	7	84 500	82 200
Statutory reserve	8	12 382	12 032
Retained earnings	8	1 937	2 904
<b>Equity</b>		<b>98 819</b>	<b>97 136</b>
<i>Equity Attributable to owners of the parent company</i>		<i>98 819</i>	<i>97 136</i>
<i>Non-controlling interest in equity</i>		-	-
Long term borrowings	9	1 717	1 731
Deferred tax liabilities	10	1 030	1 139
Non-current provisions for employee benefits	10	151	194
<b>Non-current liabilities</b>		<b>2 898</b>	<b>3 064</b>
Trade and other payables	11	4 721	6 583
Short term borrowings	9	10 771	10 324
Current borrowings and current portion of non-current borrowings	11	125	-
Current tax liabilities	11	123	204
<b>Current liabilities</b>		<b>15 740</b>	<b>17 111</b>
<b>Liabilities</b>		<b>18 638</b>	<b>20 175</b>
<b>Equity and liabilities</b>		<b>117 457</b>	<b>117 311</b>

Date of preparation: 18.04.2022

Executive director:

Biser Georgiev

Prepared by:

Petya Moneva

Date of certification: 21.04.2022

Auditor:

Asen Kitov




**Tchaikapharma High Quality Medicines Inc.**  
**Consolidated statement of comprehensive income**  
**as of 31 december 2021**

	Application	2021 BGN'000	2020 BGN'000
Revenue	12	42 431	40 105
Other income	12	124	283
Raw materials and consumables used	13	(15 583)	(14 320)
Services expens	13	(15 097)	(14 085)
Depreciation and amortisation expense	13	(3 877)	(4 231)
Employee benefits expense	13	(5 680)	(4 960)
Impairment loss on financial assets		-	(50)
Other expense by nature	13	(776)	(602)
Cost of sales	13	(1 105)	(817)
Changes in inventories of finished goods and work in progress	12,13	1 020	(784)
Finance income	14	507	521
Finance costs	14	(400)	(436)
<b>Profit Loss before tax</b>		<b>1 564</b>	<b>624</b>
Current tax expense income	15	(168)	(20)
<b>Profit Loss</b>		<b>1 396</b>	<b>604</b>
<i>Profit Loss attributable to owners of the parent company</i>		1 396	604
<i>Profit Loss attributable to non-controlling interests</i>		-	-
Other Comprehensive income before tax gains		246	-
Other Comprehensive income net of tax	10,15	(31)	(7)
Revaluation of defined benefit pension funds	15	80	(4)
Changes due to deferred tax for pension funds	10,15	(8)	-
<b>Other comprehensive income</b>		<b>287</b>	<b>(11)</b>
<i>Profit Loss attributable to owners of the parent company</i>		287	(11)
<i>Profit Loss attributable to non-controlling interests</i>		-	-
<b>Comprehensive income</b>		<b>1 683</b>	<b>593</b>
<i>Profit Loss attributable to owners of the parent company</i>		<i>1 683</i>	<i>593</i>
<i>Profit Loss attributable to non-controlling interests</i>		<i>-</i>	<i>-</i>
Earnings per share / in BGN per 1 share /		0.02	0.007
Date of preparation: 18.04.2022 г.			

Executive director:

  
Biser Georgiev

Prepared by:

  
Petya Moneva

Date of certification: 21.04.2022

Auditor:   
Asen Kitov



**Tchaikapharma High Quality Medicines Inc.**  
**Consolidated Cash flow statement**  
**as of 31 december 2021**

Application	2021 BGN'000	2020 BGN'000
<b>Cash flows from operating activities</b>		
Receipts from sales of goods and rendering of services	33 931	35 208
Payments to suppliers for goods and services	(22 965)	(22 940)
Payments to and on behalf of employees	(5 518)	(4 802)
Effect of exchange rate changes on cash and cash equivalents	(30)	(19)
Income taxes paid classified as operating activities	(218)	(352)
Other cash receipts from operating activities	3	4
Other cash payments from operating activities	(3 180)	(3 613)
<b>Cash flows from used in operating activities</b>	<b>2 023</b>	<b>3 486</b>
<b>Cash flows from investing activities</b>		
Purchase of other longterm assets classified as investing activities	(1 573)	(2 907)
<b>Cash flows from used in investing activities</b>	<b>(1 573)</b>	<b>(2 907)</b>
<b>Cash flows from financial activities</b>		
Dividends paid classified as financing activities	(200)	(196)
Proceeds from borrowings classified as financing activities	199	200
Repayments of borrowings classified as financing activities	(201)	(201)
Payments of lease liabilities classified as financing activities	(459)	(358)
Other inflows of cash classified as financing activities	204	-
<b>Cash flows from used in financial activities</b>	<b>(457)</b>	<b>(555)</b>
<b>Increase/Decrease in cash and cash equivalents</b>	<b>(7)</b>	<b>24</b>
<b>Cash and cash equivalents</b>	<b>6</b>	<b>40</b>
<b>Cash and cash equivalents</b>	<b>6</b>	<b>64</b>

Date of preparation: 18.04.2022

Executive director:

Biser Georgiev

Date of certification: 21.04.2022

Prepared by:

Petya Moneva

Auditor:

Asen Kitov



**Tchaikapharma High Quality Medicines Inc.**  
**Consolidated statement on changes in equity**  
**as of 31 december 2021**

	Property plant and equipme nt revaluati on	Other reserves	Retained earnings	Equity abstract	Equity Attributab le to owners of the parent company	Non- controllin g interest in equity	
	Issued capital	surplus					
	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	
<b>Balance as of 01.01.2020</b>	<b>82 200</b>	<b>4 099</b>	<b>7 676</b>	<b>2 568</b>	<b>96 543</b>	<b>96 543</b>	-
Profit Loss	-	-	-	604	604	604	-
Other comprehensive income	-	-11	-	-	-11	-11	-
<b>Comprehensive income</b>	-	<b>-11</b>	-	<b>604</b>	<b>593</b>	<b>593</b>	-
Increase/Decrease through appropriation of retained earnings	-	-	268	(268)	-	-	-
<b>Total income expense</b>	-	-	<b>268</b>	<b>(268)</b>	-	-	-
<b>Balance as of 31.12.2020</b>	<b>82 200</b>	<b>4 088</b>	<b>7 944</b>	<b>2 904</b>	<b>97 136</b>	<b>97 136</b>	-
<b>Balance as of 01.01.2021</b>	<b>82 200</b>	<b>4 088</b>	<b>7 944</b>	<b>2 904</b>	<b>97 136</b>	<b>97 136</b>	-
Profit Loss	-	-	-	1 396	1 396	1 396	-
Other comprehensive income	-	287	-	-	287	287	-
<b>Comprehensive income</b>	-	<b>287</b>	-	<b>1 396</b>	<b>1 683</b>	<b>1 683</b>	-
Increase/Decrease through appropriation of retained earnings	2 300	-	63	(2 363)	-	-	-
<b>Total income expense</b>	<b>2 300</b>	-	<b>63</b>	<b>(2 363)</b>	-	-	-
<b>Balance as of 31.12.2021</b>	<b>84 500</b>	<b>4 375</b>	<b>8 007</b>	<b>1 937</b>	<b>98 819</b>	<b>98 819</b>	-


Date of preparation: 18.04.2022

Executive director:



Biser Georgiev

Prepared by:



Petya Moneva

Date of certification: 21.04.2022

Auditor:



Asen Kitov

